Opinion: The global diabetes crisis few are talking about
In the numbers game of disease statistics, type 1 diabetes takes a back seat to…
Category: advocacy
Opinion: Why the U.S. needs a public benefit biopharma industry
The biopharma industry is failing Americans, economically and medically. U.S. biotechnology and pharmaceutical companies, like…
Opinion: Listen: The Supreme Court set public health back 50 years. The next term could be even worse
It took the U.S. Supreme Court just seven days last June to set back public…
Opinion: Medicare’s cuts to home health are a step in the wrong direction
My grandmother lived at the top of a hill overlooking the magical mountains and valleys…
Opinion: The cost of doing nothing: Congress is missing a rare opportunity to improve FDA policies and help people with deadly illnesses
Congress has taken the necessary step of including critical reauthorizations for the Prescription Drug User…
Opinion: Interoperability can’t wait: Don’t delay information blocking rules
Interoperability is a word you seldom hear uttered outside the health care sector (though there…
Opinion: Needed: stricter screening of gene synthesis orders, customers
Scientists rely on gene synthesis technologies as a research tool for everything from basic research…
Opinion: Will there be a Supreme assault on public health?
In just seven days last June, the U.S. Supreme Court set back public health by…
Opinion: How the Inflation Reduction Act can help decarbonize the health care industry
The climate crisis — the greatest threat to human health in history — is often…
.jpg)
Opinion: Maternal-fetal surgery is not an alternative to abortion care
Every day, pregnant people across the United States get the news that the futures they…
Opinion: FDA: Ignore a pharma company’s deceptive racial equity argument for keeping Makena, an ineffective preterm labor drug
In an effort to sway the Food and Drug Administration not to withdraw accelerated approval…
Opinion: Gender-affirming care should be embraced, not met with vitriol and bomb threats
As a pediatrician and a parent of a transgender son, I have become increasingly alarmed…
Opinion: Public health agencies: learn from NASA about regaining the public’s trust
The amazing images of the Cartwheel Galaxy captured by the James Webb Space Telescope this…
Opinion: Termination is the safest course for some high-risk pregnancies. Dobbs decision threatens that care
Ava was excited about her pregnancy. As her rheumatologists, we were anxious about it. Her…
STAT+: Patients for Affordable Drugs taps new leader
WASHINGTON — One of Washington’s most prominent drug pricing patient groups is tapping an advocate who…
Opinion: FDA and USDA need to get on board with the CDC about reducing antibiotic use in raising animals for food
The overuse of antibiotics and other antimicrobials in raising farm animals for food may not…
Opinion: A challenge trial can streamline testing of hepatitis C vaccines
Trade-offs in medicine can be harsh, even when clearly necessary. Chemotherapy can save people from…
Opinion: Health care needs a Black Friday sale: the case for legalizing discounts on medical services
The best time to buy a car is at model year-end sales, and Black Friday…
Opinion: Medicare needs to update its wheelchair coverage for the 21st century
Both of us have spent much of our lives in wheelchairs. But not just any…
Opinion: Launch prices: tackling the next drug pricing challenge
The passage of the Inflation Reduction Act brings a new era to drug pricing in…
Opinion: Congress should not compel Medicare to pay for liquid biopsies
When the two Republican senators from Mississippi cosponsor legislation with the two Democratic senators from…
Opinion: Listen: A doctor with ALS laments the slow pace for drug approval
During his long career as a pediatric oncologist and cancer researcher, William Woods thought highly…
Opinion: The FDA needs to be more flexible in assessing treatments for rare diseases, like the one that seemed to help my son
Every time I read about clinical trials testing possible treatments for rare diseases, I think…
Opinion: People with terminal cancer need to know they are dying. Doctors shouldn’t withhold that information
I have worn many hats professionally. The most uncomfortable one is “doctor friend.” At best,…
Opinion: ‘Food is medicine’ interventions should be the main course at White House nutrition conference
Much of the public’s perceptions around food as an intervention for health are dated. So…
Opinion: As hospitals raise their prices, U.S. workers and businesses suffer
Despite a recent taxpayer-subsidized boon, the hospital industry spent the last several months lobbying for…
Opinion: Polio in New York: A call to action for U.S. pediatricians and public health to work together
A nightmare for pediatricians became a reality earlier this month: Polio, which was previously thought…
Opinion: Monkeypox public health response is lagging for LGBTQ+ community
I’m a 29-year-old gay man living in New York City during the first major wave…
Opinion: The Biden-Harris administration needs to end fake abortion clinics
In the aftermath of the Supreme Court’s decision to overturn Roe v. Wade, President Biden…
Opinion: History doesn’t have to repeat itself with stigma and monkeypox
Ricky (not his real name), is a patient of mine: a young, gay man with…
Opinion: As a pediatric cancer researcher, I admired the FDA. Then I got ALS
Amyotrophic lateral sclerosis (ALS), as I have unfortunately come to learn, is a terrible disease…
Opinion: Report: More people should be tested for potential exposure to ‘forever chemicals’
Nearly every American has been exposed at some point to a class of compounds known…
In a momentous vote for Pelosi, House sends drug pricing reforms to President Biden’s desk
WASHINGTON — Fifteen years later, House Speaker Nancy Pelosi is fulfilling one of her first campaign…
STAT+: Health care industry swarms Washington as surprise billing rules get ironed out
Solving surprise medical bills was supposed to be straightforward. It has been anything but. Already,…
A chaotic sprint to lower insulin prices and AIDS activists go after Biden on monkeypox
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
The view on drug pricing from Wall Street, a pharma-friendly Dem holds firm, and what’s next for a big telehealth bill
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
Opinion: The Morris ALS Principles: A model for empowering all disease communities
The FDA’s decision to delay its highly anticipated review of AMX0035, a new drug for…
.jpg)
Opinion: Value-based payment has produced little value. It needs a time-out
The value-based payment crusade is now two decades old. But despite the tens of billions…
Opinion: The FDA needs to get ready to evaluate synthetic cells, the next generation of therapeutics
Expanding new medical treatments requires pushing — and sometimes breaking — the boundaries of what…
STAT+: ‘What can we do?’: Pharma lobbyists face their biggest test in a decade, as Democrats barrel toward a vote on drug pricing
WASHINGTON — The pharmaceutical industry, notorious for its deep pockets and aggressive lobbying tactics, has a…
Opinion: Working with Indigenous allies is the ethical way to develop psychedelic-based pharmaceuticals
Psychedelic medicine is having a moment of tremendous growth and innovation as researchers rediscover its…
PhRMA and BIO descend on D.C. & unpacking the Senate’s FDA funding drama
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
Opinion: Keep equity in mind when moving to value-based payment
Value-based care champions health and justice by focusing on outcomes rather than on units of…
Opinion: Free the pill — and make it free
This month, HRA Pharma announced it had submitted the first-ever application to the Food and…
Major abortion pill maker GenBioPro hires its first lobbyists in Washington
WASHINGTON – GenBioPro, which sells the generic version of the abortion pill mifepristone, hired its…
Opinion: Opioid-pushing executives should get jail time, not fines
The first time I heard the word “Oxy” was President’s Day, 2001, as my 18-year-old…
Opinion: Secrecy: A demon of gene therapy’s past bedevils its future
Twenty-three years ago, the field of gene therapy was bursting with the promise of breakthrough…
Opinion: Dobbs decision will rob many medical students of essential abortion training
As medical students — the next generation of physicians — we believe that the Supreme…
Opinion: Hospitals and for-profit PBMs are diverting billions in 340B savings from patients in need
America’s economically disadvantaged patients can point in two directions when talking about what is wrong…
Opinion: THC ingestion by young kids highlights the need to tighten inadequate packaging regulations
Tetrahydrocannabinol (THC), the psychoactive ingredient in marijuana, is finding its way into the hands and…